A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Главный автор: | Islam, Nahidul |
---|---|
Другие авторы: | Talukder, Mesbah |
Формат: | Диссертация |
Язык: | English |
Опубликовано: |
Brac University
2023
|
Предметы: | |
Online-ссылка: | http://hdl.handle.net/10361/22025 |
Схожие документы
-
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
по: Afroza, Halima
Опубликовано: (2024) -
Biologics and Biosimilars as Treatment Options for Psoriasis
по: Moya, Amena Khatun
Опубликовано: (2023) -
Association of GLP-1 receptor agonists and risk of pancreatitis: a pharmacovigilance study based on FAERS database
по: Bishakha, Adwiza Chakraborty
Опубликовано: (2024) -
Safety and efficacy of dutasteride for male Androgenetic Alopecia
по: Islam, S.M. Zahidul
Опубликовано: (2024) -
Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a pharmacovigilance study
по: Khandker, Tahia Anjum
Опубликовано: (2024)